Potent Selectivity: Nimbus Entrusts IRAK4 Program To Genentech
This article was originally published in Scrip
Even the most ambitious early-stage biopharma has to prioritize which programs it will take on itself and which might advance more quickly and fully in the hands of a more-experienced and deeper-pocketed partner. Having used its computational chemistry platform to generate IRAK4 inhibitors with potential in autoimmune disease and B-cell lymphomas, Nimbus Therapeutics has licensed global rights to that program to Genentech Inc.
Register for our free email digests: